Future antibiotics scenarios: is the tide starting to turn?

International Journal of Antimicrobial Agents

Volumn 34, Issue 1, 2009, Pages 15-20

  Theuretzbacher, Ursula ^a  

^a Center For Anti Infective Agents Vienna   (Austria)

Author keywords

Antibacterial pipeline; Antibiotics; Development; Gram negative; Resistance

Indexed keywords

ACHN 490; AFN 1252; AMADACYCLINE; ANTIBIOTIC AGENT; BACTERIAL VACCINE; BAL 30072; BC 3205; CB 182804; CEFTAROLINE; CEFTOBIPROLE; CEM 101; DALBAVANCIN; DELAFLOXACIN; FR 264205; IC 43; ICLAPRIM; KB 001; KBPA 101; NEMONOXACIN; NXL 103; NXL 105; ORITAVANCIN; PAGIBAXIMAB; PLATENSIMYCIN; PMX 30063; PZ 601; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADEZOLID; RWJ 416457; RX 1741; RX 3341; TD 1792; TELAVANCIN; TETRACYCLINE DERIVATIVE; TOREZOLID; TR 701; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 710; WCK 771; ZABOFLOXACIN;

ANTIBIOTIC THERAPY; DRUG INDUSTRY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS;

EID: 67349272763     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.02.005     Document Type: Short Survey

References (37)

1. Souli M., Galani I., and Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 13 47 (2008) pii=19045
2. Rossolini G.M., and Mantengoli E. Antimicrobial resistance in Europe and its potential impact on empirical therapy. Clin Microbiol Infect 14 Suppl. 6 (2008) 2-8
3. Gould I.M. Who's winning the war?. J Antimicrob Chemother 62 Suppl. 3 (2008) iii3-iii6
4. Arias C.A., and Murray B.E. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N Engl J Med 360 (2009) 439-443
5. Boggs A.F., and Miller G.H. Antibacterial drug discovery: is small pharma the solution?. Clin Microbiol Infect 10 Suppl. 4 (2004) 32-36
6. Gyssens I.C. All EU hands to the EU pumps: the Science Academies of Europe (EASAC) recommend strong support of research to tackle antibacterial resistance. Clin Microbiol Infect 14 (2008) 889-891
7. van de Sande-Bruinsma N., Grundmann H., Verloo D., Tiemersma E., Monen J., Goossens H., et al. Antimicrobial drug use and resistance in Europe. Emerg Infect Dis 14 (2008) 1722-1730
8. Manallack D.T., Crosby I.T., Khakham Y., and Capuano B. Platensimycin: a promising antimicrobial targeting fatty acid synthesis. Curr Med Chem 15 (2008) 705-710
9. Yang L.P., and Keam S.J. Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 68 (2008) 855-873
10. O'Fallon E., Pop-Vicas A., and D'Agata E. The emerging threat of multidrug-resistant Gram-negative organisms in long-term care facilities. J Gerontol A Biol Sci Med Sci (2009) January 27 [Epub ahead of print]
11. Spellberg B., Guidos R., Gilbert D., Bradley J., Boucher H.W., Scheld W.M., et al. Infectious Diseases Society of America. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46 (2008) 155-164
12. Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 197 (2008) 1079-1081
13. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., and Bartlett J.G. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 42 (2006) 657-668
14. Boucher H.W., Talbot G.H., Bradley J.S., Edwards J.E., Gilbert D., Rice L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 1-12
15. O'Neill A.J. New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria. Expert Opin Investig Drugs 17 (2008) 297-302
16. Theuretzbacher U., and Toney J.H. Nature's clarion call of antibacterial resistance: are we listening?. Curr Opin Investig Drugs 7 (2006) 158-166
17. Takeda S., Nakai T., Wakai Y., Ikeda F., and Hatano K. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 51 (2007) 826-830
18. Livermore D.M., Mushtaq S., Warner M., Miossec C., and Woodford N. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J Antimicrob Chemother 62 (2008) 1053-1056
19. Mushtaq S., Warner M., and Livermore D. Activity of novel monobactam BAL30072 against multiresistant non-fermenters. 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 25-28 October 2008; Washington, DC (2008), ASM Press, Washington, DC [abstract F1-1164]
20. Dudley M.N., Loutit J., and Griffith D.C. Aerosol antibiotics: considerations in pharmacological and clinical evaluation. Curr Opin Biotechnol 19 (2008) 637-643
21. Wang Y.C., and Lipsitch M. Upgrading antibiotic use within a class: tradeoff between resistance and treatment success. Proc Natl Acad Sci USA 103 (2006) 9655-9660
22. Robinson J.A., Demarco S., Gombert F., Moehle K., and Obrecht D. The design, structures and therapeutic potential of protein epitope mimetics. Drug Discov Today 13 (2008) 944-951
23. Vance R.E., Rietsch A., and Mekalanos J.J. Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo. Infect Immun 73 (2005) 1706-1713
24. Hawkey P.M. The growing burden of antimicrobial resistance. J Antimicrob Chemother 62 Suppl. 1 (2008) i1-i9
25. Michalopoulos A., and Falagas M.E. Colistin and polymyxin B in critical care. Crit Care Clin 24 (2008) 377-391
26. Falagas M.E., Rafailidis P.I., Matthaiou D.K., Virtzili S., Nikita D., and Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents 32 (2008) 450-454
27. Paterson D.L. Impact of antibiotic resistance in gram-negative bacilli on empirical and definitive antibiotic therapy. Clin Infect Dis 47 Suppl. 1 (2008) S14-S20
28. Kollef M.H. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 47 Suppl. 1 (2008) S3-S13
29. Malhotra-Kumar S., Haccuria K., Michiels M., Ieven M., Poyart C., Hryniewicz W., et al. Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant Enterococcus species. J Clin Microbiol 46 (2008) 1577-1587
30. Carroll K.C. Rapid diagnostics for methicillin-resistant Staphylococcus aureus: current status. Mol Diagn Ther 12 (2008) 15-24
31. Nolte F.S. Molecular diagnostics for detection of bacterial and viral pathogens in community-acquired pneumonia. Clin Infect Dis 47 Suppl. 3 (2008) S123-S126
32. Lesko L.J. Personalized medicine: elusive dream or imminent reality?. Clin Pharmacol Ther 81 (2007) 807-816
33. Richmond T.D. The current status and future potential of personalized diagnostics: streamlining a customized process. Biotechnol Annu Rev 14 (2008) 411-422
34. Fleming T.R., and Powers J.H. Issues in noninferiority trials: the evidence in community-acquired pneumonia. Clin Infect Dis 47 Suppl. 3 (2008) S108-S120
35. Dong J., Olano J.P., McBride J.W., and Walker D.H. Emerging pathogens: challenges and successes of molecular diagnostics. J Mol Diagn 10 (2008) 185-197
36. Forrest G.N., Roghmann M.C., Toombs L.S., Johnson J.K., Weekes E., Lincalis D.P., et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 52 (2008) 3558-3563
37. Shlaes D.M. The abandonment of antibacterials: why and wherefore?. Curr Opin Pharmacol 3 (2003) 470-473